# EDGAR Filing Document

**Accession Number:** 0001892500
**File Stem:** 0000000000-26-001956
**Filing Date:** 2026-2
**Character Count:** 2212
**Document Hash:** 0d8604c134a51b7ba5ebcfa261594d05
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001956.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0000000000-26-001956

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260225

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clearmind Medicine Inc.
- **CENTRAL INDEX KEY:** 0001892500
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293521

**BUSINESS ADDRESS:**
- **STREET 1:** 101-1220 WEST 6TH AVENUE
- **CITY:** VANCOUVER, BRITISH COLUMBIA
- **STATE:** Z4
- **ZIP:** V6H1A5
- **BUSINESS PHONE:** 972-54-5704749

**MAIL ADDRESS:**
- **STREET 1:** 101-1220 WEST 6TH AVENUE
- **CITY:** VANCOUVER, BRITISH COLUMBIA
- **STATE:** Z4
- **ZIP:** V6H1A5
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-26-017379

## Text-Extract

```

                                                           February 25, 2026

Adi Zuloff-Shani
Chief Executive Officer
Clearmind Medicine Inc.
101     1220 West 6th Avenue
Vancouver, British Columbia V6H1A5

       Re: Clearmind Medicine Inc.
           Registration Statement on Form F-3
           Filed February 17, 2026
           File No. 333-293521
Dear Adi Zuloff-Shani:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Lauren Hamill at 303-844-1008 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    David Huberman

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._